Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-19 of 19
Keywords: Peptide receptor radionuclide therapy
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Mahesh Kumar Padwal, Rahul Vithalrao Parghane, Avik Chakraborty, Aman Kumar Ujaoney, Narasimha Anaganti, Sandip Basu, Bhakti Basu
Journal:
Neuroendocrinology
Neuroendocrinology 1–14.
Published Online: 03 December 2024
... was to profile the peripheral blood transcriptome through RNA-Seq and investigate the association of the systemic cancer hallmarks with progression-free survival, in peptide receptor radionuclide therapy (PRRT)-treated GEP-NET patients. Methods: The cohorts were discovery cohort [PRRT-naïve well-differentiated...
Journal Articles
Wei Ying Tham, Hian Liang Huang, David Wai Meng Tai, John C. Allen Jr., Jacqueline S.G. Hwang, Lih Ming Loh, Brian K.P. Goh, Simon Y.K. Ong, Peng Chin Kek, Damien M.Y. Tan, David C.E. Ng, Kelvin S.H. Loke
Journal:
Neuroendocrinology
Neuroendocrinology (2024) 114 (9): 840–847.
Published Online: 26 March 2024
...Wei Ying Tham; Hian Liang Huang; David Wai Meng Tai; John C. Allen Jr.; Jacqueline S.G. Hwang; Lih Ming Loh; Brian K.P. Goh; Simon Y.K. Ong; Peng Chin Kek; Damien M.Y. Tan; David C.E. Ng; Kelvin S.H. Loke Purpose: Peptide receptor radionuclide therapy (PRRT) is a targeted molecular therapy used...
Journal Articles
Subject Area:
Karger e-Journal Backfile Collection 2023
,
Endocrinology
,
Neurology and Neuroscience
Minmin Li, David L. Chan, Gonzalo Tapia Rico, Gabrielle Cehic, Ben Lawrence, David Wyld, David A. Pattison, Grace Kong, Rodney Hicks, Michael Michael, Andrew Ddembe Kiberu, Jennifer Lim, Roderick Clifton-Bligh, Venessa Tsang, Paul J. Roach, John Leyden, Connie I. Diakos, Timothy J. Price, Nick Pavlakis
Journal:
Neuroendocrinology
Neuroendocrinology (2023) 113 (3): 281–288.
Published Online: 07 March 2023
... Pavlakis Hormonal crises are a rare but increasingly recognized phenomenon following peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms (NENs). Due to the paucity of published studies, approaches to the identification, prevention, and management of risk factors...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (11): 1086–1098.
Published Online: 19 March 2021
... with respect to peptide receptor radionuclide therapy (PRRT). This comprehensive review evaluates the data supporting approved therapies for GEP-NETs and recommendations for therapeutic sequencing with a focus on how PRRT currently fits within sequencing algorithms. The current recommendations for PRRT...
Journal Articles
Stine Karlsen Oversoe, Boe Sandahl Sorensen, Elizaveta Mitkina Tabaksblat, Henning Gronbaek, Jens Kelsen
Journal:
Neuroendocrinology
Neuroendocrinology (2022) 112 (1): 43–50.
Published Online: 18 January 2021
... = 50) and pNET ( n = 20). Plasma cfDNA levels were determined by droplet digital PCR for the beta-2-microglobulin gene every 6 months during a period of 3 years, including in a subgroup of 19 patients during peptide receptor radionuclide therapy (PRRT) therapy. Results: cfDNA levels were higher in both...
Journal Articles
Alberto Bongiovanni, Chiara Liverani, Flavia Foca, Valentina Fausti, Giandomenico Di Menna, Laura Mercatali, Alessandro De Vita, Nada Riva, Sebastiano Calpona, Giacomo Miserocchi, Chiara Spadazzi, Claudia Cocchi, Toni Ibrahim
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (9): 895–906.
Published Online: 20 November 2020
... validated or investigated in prospective clinical trials, including somatostatin analogs (SSAs), peptide receptor radionuclide therapy (PRRT), multi-kinase inhibitors such as sunitinib, axitinib, lenvatinib, and pazopanib, and the mammalian target of rapamycin inhibitor, everolimus [ 10-13 ]. Platinum...
Journal Articles
Aimee R. Hayes, Ingrid Y.F. Mak, Nicholas Evans, Rishi Naik, Alexander Crawford, Bernard Khoo, Ashley B. Grossman, Shaunak Navalkissoor, Jennifer Watkins, Tu Vinh Luong, Dalvinder Mandair, Christos Toumpanakis, Christina Thirlwell, Martyn E. Caplin, Tim Meyer
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (9): 863–875.
Published Online: 18 September 2020
... neuroendocrine tumours (PNET) was analysed separately. These patients had received 234 lines of treatment (105 chemotherapy, 82 molecular targeted therapy, and 47 peptide receptor radionuclide therapy [PRRT]). In the G2 cohort, TTF and TTP were superior for PRRT compared with both chemotherapy and molecular...
Journal Articles
Anna Sundlöv, Katarina Sjögreen-Gleisner, Jan Tennvall, Ludvig Dahl, Johanna Svensson, Anna Åkesson, Peter Bernhardt, Ola Lindgren
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (4): 344–353.
Published Online: 08 April 2020
... indicated radiation-induced damage to the pituitary gland as a probable cause. 177 Lu-DOTATATE Peptide receptor radionuclide therapy Pituitary Radiotherapy Neuroendocrine tumor Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE is an approved treatment for metastatic...
Journal Articles
Katarzyna Fröss-Baron, Ulrike Garske-Roman, Staffan Welin, Dan Granberg, Barbro Eriksson, Tanweera Khan, Mattias Sandström, Anders Sundin
Journal:
Neuroendocrinology
Neuroendocrinology (2021) 111 (4): 330–343.
Published Online: 25 February 2020
... pancreatic neuroendocrine tumors (PanNETs), previously pretreated with chemothe-r-apy, undergoing peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE. Methods: A total of 102 patients with advanced PanNETs, previously pretreated with one (67%) or several (33%) lines of chemotherapy, were...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2020) 110 (7-8): 662–670.
Published Online: 10 October 2019
...Ulrika Jahn; Ezgi Ilan; Mattias Sandström; Ulrike Garske-Román; Mark Lubberink; Anders Sundin Introduction: Peptide receptor radionuclide therapy (PRRT) has during the last few years been frequently used in patients with progressive, disseminating, well-differentiated neuroendocrine tumors (NETs...
Journal Articles
Elettra Merola, Vikas Prasad, Andreas Pascher, Ulrich-Frank Pape, Ruza Arsenic, Timm Denecke, Uli Fehrenbach, Bertram Wiedenmann, Marianne Ellen Pavel
Journal:
Neuroendocrinology
Neuroendocrinology (2020) 110 (6): 517–524.
Published Online: 05 September 2019
... of peritoneal implants (HR: 1.10; 95% CI: 1.02–1.20; p = 0.01). Patients with diffuse PC treated with peptide receptor radionuclide therapy (PRRT) showed peritoneal progression in 37.5% of cases, and bowel obstruction or ascites in 28.1%. Better peritoneal disease control was observed in cases receiving...
Journal Articles
Jonas Ahlstedt, Edvin Johansson, Marie Sydoff, Helena Karlsson, Eddie Thordarson, Magnus Gram, Olof Eriksson
Journal:
Neuroendocrinology
Neuroendocrinology (2020) 110 (1-2): 130–138.
Published Online: 19 April 2019
...Jonas Ahlstedt; Edvin Johansson; Marie Sydoff; Helena Karlsson; Eddie Thordarson; Magnus Gram; Olof Eriksson Background/Aims: Peptide receptor radionuclide therapy (PRRT) is becoming clinical routine for management of neuroendocrine tumours. The number of PRRT cycles is correlated with treatment...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2019) 109 (4): 287–298.
Published Online: 12 March 2019
.... There is currently intense research interest in the value of radionuclide therapy for neuroendocrine tumours, including phaeochromocytoma and paraganglioma, with either iodine-131 ( 131 I)-radiolabelled metaiodobenzylguanidine or very recently peptide receptor radionuclide therapy (PRRT), and the most important...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2019) 108 (3): 256–264.
Published Online: 23 October 2018
...Shaunak Navalkissoor; Ashley Grossman Neuroendocrine tumours (NETs) are being seen increasingly frequently, but to date only complete surgical resection is curative. However, among the various therapeutic options, peptide receptor radionuclide therapy, linking a radioactive moiety to an octreotide...
Journal Articles
Rodney J. Hicks, Dik J. Kwekkeboom, Eric Krenning, Lisa Bodei, Simona Grozinsky-Glasberg, Rudolf Arnold, Ivan Borbath, Jaroslaw Cwikla, Christos Toumpanakis, Greg Kaltsas, Philippa Davies, Dieter Hörsch, Eva Tiensuu Janson, John Ramage, all other Antibes Consensus Conference participants
Journal:
Neuroendocrinology
Neuroendocrinology (2017) 105 (3): 295–309.
Published Online: 13 April 2017
... The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2016) 103 (5): 432–439.
Published Online: 10 June 2015
..., instructions or products referred to in the content or advertisements. Objective response Pancreatic neuroendocrine tumors Radiopeptide chemotherapy Peptide receptor radionuclide therapy The management of neuroendocrine tumors (NETs) has been revolutionized by the advent of 68 Ga-octreotate...
Journal Articles
Journal:
Neuroendocrinology
Neuroendocrinology (2014) 99 (2): 108–117.
Published Online: 04 April 2014
...Murali Kesavan; Phillip G. Claringbold; J. Harvey Turner Background: The combination of radiopeptide therapy [peptide receptor radionuclide therapy (PRRT)] with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential...
Journal Articles
Maddalena Sansovini, Stefano Severi, Alice Ambrosetti, Manuela Monti, Oriana Nanni, Anna Sarnelli, Lisa Bodei, Lucia Garaboldi, Mirco Bartolomei, Giovanni Paganelli
Journal:
Neuroendocrinology
Neuroendocrinology (2013) 97 (4): 347–354.
Published Online: 22 May 2013
...Maddalena Sansovini; Stefano Severi; Alice Ambrosetti; Manuela Monti; Oriana Nanni; Anna Sarnelli; Lisa Bodei; Lucia Garaboldi; Mirco Bartolomei; Giovanni Paganelli Background: We evaluated the activity and safety profile of 177 Lu-DOTATATE peptide receptor radionuclide therapy (Lu-PRRT...
Journal Articles
Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy
Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Marion de Jong, Eric P. Krenning, Dik J. Kwekkeboom
Journal:
Neuroendocrinology
Neuroendocrinology (2013) 97 (1): 74–85.
Published Online: 10 January 2012
... options are limited. A relatively new therapeutic modality, peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, is currently available in a number of mostly European centers. Complete and partial responses obtained after treatment with [ 90 Y-DOTA⁰,Tyr 3 ]octreotide...